More than 75 million people worldwide have been infected with human immunodeficiency
virus (HIV), and there are now approximately 37 million individuals living with the infection …

The introduction of potent combination therapies in the mid-90s had a tremendous effect on
AIDS mortality. However, drug resistance has been a major factor contributing to …

It is important to realize that guidelines cannot always account for individual variation among
patients. They are not intended to supplant physician judgment with respect to particular …

Background Standard first-line antiretroviral therapy for HIV-1 infection includes two
nucleoside or nucleotide reverse transcriptase inhibitors (NtRTIs), but these drugs have …

Background Daily oral triple therapy is effective at halting HIV disease progression, but can
have toxic effects and is costly. We investigated whether dual therapy with lopinavir and …

ABSTRACT A goal of HIV therapy is to sustain suppression of the plasma viral load below
the detection limits of clinical assays. However, widely followed treatment guidelines diverge …

HIV-1 protease inhibitors (PIs) are among the most effective antiretroviral drugs. They are
characterized by highly cooperative dose-response curves that are not explained by current …

BACKGROUND: Uncertainty exists about the best treatment for people with HIV-1 who have
virological failure with first-line combination antiretroviral therapy of a non-nucleoside …

Despite the high inhibition of viral replication achieved by current anti-HIV drugs, many
patients fail treatment, often with emergence of drug-resistant virus. Clinical observations …

Alternative combinations of antiretrovirals (ARVs) are desired to increase treatment options
for HIV-infected patients. PROGRESS was a randomized, open-label, 96-week pilot study …